Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by Quentin30on Jun 05, 2023 8:47am
278 Views
Post# 35480023

oh dear

oh dearLike I said 6 months ago, the triplet therapy needed to show huge improvement over the doublet... and so here we are with results... triplet with CPI did nothing. All the noteable dreamers were too busy getting dizzy with multi-billion dollar valuations to ask the question, what IF Pela+Pax+CPI does not work...

trading today will tell us what exactly what the market thinks about this 'grounbreaking data..."

The PFS difference shown is great, let's now hope that evidences as even better OS data for the doublet. But they need to get this Phase III underway..

They should be ready to go, because they ought to have been planning for either scenario. 

hope you all like waiting.. as I still don't see the phase III getting underway in 2023.

 
<< Previous
Bullboard Posts
Next >>